Debiopharm ventures into antibiotics with TCG deal

Debiopharm Group (Lausanne, Switzerland) partnered with contract research services company TCG Lifesciences Ltd. (Kolkata, India) to exclusively discover and develop an undisclosed class of antibiotics against drug-resistant bacteria for hospital-acquired (nosocomial) infections. Debiopharm has already licensed the first compound from TCG, Debio 1348, which is in discovery. The partners could not be reached for details. ...